Navigation Links
Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board
Date:5/6/2008

BERKELEY HEIGHTS, N.J., May 6 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced today that the Company has received notification from the NASDAQ Listing Qualifications Panel that the Company had failed to demonstrate its ability to sustain compliance with the minimum stockholders' equity requirement for continued listing on The NASDAQ Capital Markets. The Panel has also determined that de-listing from The NASDAQ Capital Markets will occur at the market open effective Tuesday, May 6, 2008.

In view of this event, the Company intends to move the trading of its common stock from The NASDAQ Capital Markets to the Over-the-Counter Bulletin Board (OTCBB) maintained by FINRA (formerly, the NASD). The Company has been advised that a "market maker" has filed the requisite Form 211 application to quote the Company's securities on the OTCBB with the Financial Industry Regulatory Authority (FINRA). The Company is not aware of any deficiencies in that application, and it is the Company's expectation that FINRA will promptly clear the market maker's application, and that the Company's securities will be eligible for trading on the OTCBB.

The Company plans to make a further announcement on the timing of the transfer to the OTCBB following formal receipt of the FINRA clearance notice. If cleared, quotations for the Company's common stock on the OTCBB will continue under the symbol GNTA. Until such formal notice is received, the Company's common stock will be traded under the symbol GNTA.PK.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dr. Elizabeth Brown Joins Argenta TEC
2. Syngenta To Build Major Global Biotech Research Center in Beijing, China
3. Genta Restructures Operations to Focus on Priority Initiatives
4. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
5. Auditors for Genta Incorporated Express Going Concern Qualification
6. Genta Announces Senior Management Changes
7. Genta Announces Common Stock Offering of Approximately $3.1 Million
8. Genta Incorporated to Present at the BIO CEO & Investor Conference
9. Genta Receives Notice of Non-Compliance With NASDAQ Rule
10. Genta Receives NASDAQ Non-Compliance Notice
11. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 /PRNewswire/ - JSS Medical Research Inc., a Montreal ... concluded the acquisition of Max Neeman International (MNI), with head office ... are located in Ahmedabad, Bangalore , ... US subsidiary, a regional office is located North Carolina, ... by the recent equity investment transaction into JSS with Capital Croissance ...
(Date:5/4/2015)... Israel , May 4, 2015  Tikcro Technologies ... its annual report on Form 20-F for the fiscal ... and Exchange Commission ("SEC"). The annual report on Form ... development of antibodies in the area of cancer immune ... superior qualities of high specificity and binding in targeting ...
(Date:5/4/2015)... TORONTO , May 4, 2015 /PRNewswire/ - ... its partners are pleased to announce the formation ... focussed on developing treatments for cancer that harness ... company represents a unique collaboration between the Children,s ... (CHEO) Research Institute, McMaster University, the Ontario Institute ...
(Date:5/4/2015)... Achieved primarily through a proprietary paraffin and stain ... 100x better detail than the industry standard. But ... microscopy methods, it needed another medium to measure its ... of reference because it represents the highest standard of ... earliest discovery days of Ultralight Histology was to reverse ...
Breaking Biology Technology:JSS Medical Canada widens its global presence across Asia/Pacific region 2JSS Medical Canada widens its global presence across Asia/Pacific region 3JSS Medical Canada widens its global presence across Asia/Pacific region 4Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 3
... NV,(Euronext Brussels: THR), a biotechnology company focused on ... it has completed,patient enrolment for its Phase II ... is to evaluate the safety and preliminary efficacy ... four and twelve hours after the onset of ...
... 8, 2008 Dendreon Corporation,(Nasdaq: DNDN ) ... registered direct offering of 8.0 million shares of ... 8.0 million shares of its common,stock. Net proceeds ... Markets LLC served as sole placement agent for ...
... Ganeden Biotech,announced that Sustenex(TM), its all-natural daily ... capsule contains at least 2,billion live probiotic ... Bacillus coagulans designed to help promote immune ... designed to survive and,thrive in the digestive ...
Cached Biology Technology:ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke 2ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke 3Dendreon Announces Closing of Registered Direct Offering 2Ganeden Biotech Takes Sustenex(TM) National with GanedenBC30 Probiotic 2Ganeden Biotech Takes Sustenex(TM) National with GanedenBC30 Probiotic 3
(Date:4/13/2015)... , April 13, 2015  higi, a leading ... ways to more fully engage with their communities around ... industry-leading, privacy protected and secure API.  ... enables the most accessible, affordable, and convenient vehicle to ... The API will allow ...
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... A new study presages a real aim of genetics: to ... of individual genetic variants for individual health. The research team, ... six novel genetic variants that are associated with lipid levels, ... power of ,genetic microscopes, has increased because the methods are ...
... Mass. Dec. 3, 2008 Interleukin-12 is a ... the human immune system. Having either too much or ... development of many diseases, including some cancers and auto-immune ... modulating interleukin-12 levels could yield new therapies for those ...
... Babraham Institute near Cambridge, supported by the Alzheimer,s ... Research Council (BBSRC), have discovered that the brain,s ... of ageing such as Alzheimer,s disease. The findings ... . Alzheimer,s disease causes nerve cells in ...
Cached Biology News:The genetic heart of the lipids 2The genetic heart of the lipids 3Novel bioreactor enhances interleukin-12 production in genetically modified tobacco plants 2Novel bioreactor enhances interleukin-12 production in genetically modified tobacco plants 3Maintaining the brain's wiring in aging and disease 2
Porcine Serum US Origin 6 Months or Older...
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
... off the clot from fasted Cynomolgus monkeys of mixed ... Anticoagulants: N-02: Citrate N-04: ... Potassium Oxalate N-10: EDTA (Na) N-03: ... CPD N-09: K3EDTA N-11: Heparin ...
adult...
Biology Products: